The Icelandic Medicines Agency has decided to limit the scope of the planned wholesale price revision to marketed originator medicines for human use, excluding permission products, "Leyfisskyld lyf" , which will not be reviewed at this time. This applies to medicines marked with "1" in the "Medicine Status" column of the pharmaceutical price list.

The revision will encompass all ATC categories, with due consideration given to applicable exemptions in accordance with the Agency's procedural guidelines.

For further details, reference is made to the previous announcement by the Icelandic Medicines Agency regarding the planned wholesale price revision for originator medicines.